News
Cipla Health ventures into antifungal product category with launch of Clocip
Cipla Health Ltd., a leading consumer healthcare brand, has forayed into the antifungal product category with the introduction of Clocip, to offer a hardworking...
News
Roche announces FDA approval of Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
Roche announced that the United States (US) FDA has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive...
Clinical Trials
Merck announces positive results phase 3 trials of gefapixant 45 mg twice daily in patients with refractory or unexplained chronic cough
Merck, known as MSD outside the United States and Canada, has announced the results from two pivotal phase 3 trials (COUGH-1 and COUGH-2) evaluating...
News
Mylan to Acquire Aspen’s Thrombosis Business in Europe
Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for...
News
Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd
Bayer, a global leader in women’s healthcare, announced that, further to its press release of August 11, 2020, it has now completed the acquisition...
News
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets in Japan from Meiji Seika Pharma
Eisai Co., Ltd. announced that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide...
Drug Research
Catalent and Exelixis Enter into Collaboration, License, and Exclusive Option Agreement to Develop ADC Leveraging SMARTag Bioconjugation Technology
Exelixis, Inc. and Catalent announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
